Denmark: Novo Nordisk acquires Embark Biotech

Embark Laboratories, a Danish biotech company that focuses on cardiometabolic disease with an emphasis on energy expenditure, has announced that Novo Nordisk, a Danish multinational pharmaceutical company, has acquired Embark Biotech, including its lead metabolic programme, and entered a three-year R&D collaboration to discover and develop novel pharmaceuticals to treat obesity and related co-morbidities. Under…

You must be a HMI Subscriber to view this content.

Subscribe Now »